CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
Vancomycin +1 moredrug
Likely dose
Vancomycin 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03462459
NCT03462459Phase 2Completed
CompareCT.gov

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

University of Wisconsin, Madison·interventional·Posted Mar 12, 2018·Updated May 25, 2025

In Brief

A Phase 2 clinical trial evaluating Vancomycin and Placebo for Recurrent Clostridium Difficile Infection and 5 related conditions. Completed, enrolled 79 participants across 2 sites.

Detailed Summary

This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized to receive either placebo or oral vancomycin in addition to their prescribed antibiotic therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
CountriesUnited States
CollaboratorsMedical College of Wisconsin, Agency for Healthcare Research and Quality (AHRQ), Henry Ford Hospital, Mayo Clinic

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 12, 2018
Enrollment StartMay 21, 2018
Primary CompletionJul 6, 2023
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 8.3 years ago

Interventions

Vancomycindrug

Vancomycin capsule, 125 mg

Placebodrug

Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule